Background:

developmental stage:Expression in neutrophils occurs in the late terminal differentiation phase.,Acts as a high affinity receptor for both nicotinic acid (also known as niacin) and (D)-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G(i)-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. Mediates nicotinic acid-induced apoptosis in mature neutrophils. Receptor activation by nicotinic acid results in reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis.,miscellaneous:The rank order of potency for the displacement of nicotinic acid binding is 5-methyl pyrazole-3-carboxylic acid = pyridine-3-acetic acid > acifran > 5-methyl nicotinic acid = acipimox >> nicotinuric acid = nicotinamide.,Belongs to the G-protein coupled receptor 1 family.,tissue specificity:Expression largely restricted to adipose tissue and spleen. Expressed on mature neutrophils but not on immature neutrophils or eosinophils.,

Classification:

Primary antibody

Alternative names:

Hydroxycarboxylic acid receptor 2 ;G-protein coupled receptor 109A;G-protein coupled receptor HM74A;Niacin receptor 1;Nicotinic acid receptor

Species reactivity:

Human, Rat, Mouse

Host:

Rabbit

Isotype:

IgG

Immunogen:

Synthesized peptide derived from human protein . at AA range: 260-340

Concentration:

1 mg/ml

Molecular weight:

Applications:

WB, ELISA

Storage:

-20°C for 1 year

More info:

Email: info@sobekbio.com

Orders:

Email: orders@sobekbio.com